Tarsus Pharmaceuticals Stock Performance
The entity has a beta of 0.52, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Tarsus Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Tarsus Pharmaceuticals is expected to be smaller as well. At this point, Tarsus Pharmaceuticals has a negative expected return of -0.12%. Please make sure to validate Tarsus Pharmaceuticals' risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis , to decide if Tarsus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Tarsus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
| Begin Period Cash Flow | 97.4 M | |
| Total Cashflows From Investing Activities | -42.1 M | |
| Free Cash Flow | -22.3 M |
Tarsus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 7,996 in Tarsus Pharmaceuticals on November 27, 2025 and sell it today you would lose (696.00) from holding Tarsus Pharmaceuticals or give up 8.7% of portfolio value over 90 days. Tarsus Pharmaceuticals is currently does not generate positive expected returns and assumes 2.4355% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Tarsus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tarsus Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Tarsus Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Tarsus Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals is not yet fully synchronised with the market data | |
| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Tarsus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 451.36 M. Net Loss for the year was (66.42 M) with profit before overhead, payroll, taxes, and interest of 278.26 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (12.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Over 97.0% of the company shares are owned by institutional investors |
Tarsus Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Tarsus Stock often depends not only on the future outlook of the current and potential Tarsus Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Tarsus Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.8 M | |
| Cash And Short Term Investments | 417.3 M |
Tarsus Pharmaceuticals Fundamentals Growth
Tarsus Stock prices reflect investors' perceptions of the future prospects and financial health of Tarsus Pharmaceuticals, and Tarsus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tarsus Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 2.17 B | ||||
| Shares Outstanding | 42.45 M | ||||
| Price To Book | 7.46 X | ||||
| Price To Sales | 8.07 X | ||||
| Revenue | 451.36 M | ||||
| EBITDA | (70.97 M) | ||||
| Cash And Equivalents | 245.36 M | ||||
| Cash Per Share | 9.20 X | ||||
| Total Debt | 218.73 M | ||||
| Debt To Equity | 0.09 % | ||||
| Book Value Per Share | 7.89 X | ||||
| Cash Flow From Operations | (12.45 M) | ||||
| Earnings Per Share | (1.99) X | ||||
| Total Asset | 562.16 M | ||||
| Retained Earnings | (426.63 M) | ||||
Things to note about Tarsus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Tarsus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tarsus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tarsus Pharmaceuticals is not yet fully synchronised with the market data | |
| Tarsus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Tarsus Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 451.36 M. Net Loss for the year was (66.42 M) with profit before overhead, payroll, taxes, and interest of 278.26 M. | |
| Tarsus Pharmaceuticals currently holds about 245.36 M in cash with (12.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.2. | |
| Over 97.0% of the company shares are owned by institutional investors |
- Analyzing Tarsus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tarsus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Tarsus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tarsus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tarsus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tarsus Pharmaceuticals' stock. These opinions can provide insight into Tarsus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Tools for Tarsus Stock
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |